Fig. 1From: A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s diseaseThe relationship between CSF Aβ42 and years to estimated clinical onset (YECO) in patients with sAD or MCI with or without abnormal PET.11C-Pittsburgh compound B (PiB) amyloid levels (A); and between CSF Aβ42 levels and chronological age in sAD and MCI patients with or without abnormal PET PiB amyloid levels (B)Back to article page